Bioventus Inc.
BVSNASDAQHealthcare● Active
$9.03
$-0.01(-0.10%)
Market Cap$611825847
P/E Ratio—
52W High$11.249
52W Low$5.81
Bioventus Inc. (BVS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BVS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.15
Est. $0.09 · +66.7%
Revenue
$0.13B
Est. $0.13B · +1.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
BVS reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.21 | — | — | — | $0.16B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $0.09 | $0.15 | +66.7% | $0.13B | $0.13B | +1.7% |
| ▲ Q1 FY2026 | Mar 5, 2026 | $0.22 | $0.24 | +9.1% | $0.16B | $0.15B | +1.9% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $0.21 | $0.15 | -30.2% | $0.14B | $0.16B | -10.9% |
| ▼ Q3 FY2025 | Aug 6, 2025 | $0.22 | $0.21 | -4.5% | $0.15B | $0.14B | +6.4% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.06 | $0.08 | +33.3% | $0.12B | $0.15B | -15.1% |
| ▲ Q1 FY2025 | Mar 11, 2025 | $0.08 | $0.15 | +87.5% | $0.15B | $0.12B | +23.4% |
| — Q4 FY2024 | Nov 5, 2024 | $0.06 | $0.06 | +0.0% | $0.14B | $0.14B | -4.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$0.15
EPS Est.
$0.09
EPS Surpr.
+66.7%
Revenue
$0.13B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
$0.24
EPS Est.
$0.22
EPS Surpr.
+9.1%
Revenue
$0.16B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
$0.15
EPS Est.
$0.21
EPS Surpr.
-30.2%
Revenue
$0.14B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
$0.21
EPS Est.
$0.22
EPS Surpr.
-4.5%
Revenue
$0.15B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.08
EPS Est.
$0.06
EPS Surpr.
+33.3%
Revenue
$0.12B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.08
EPS Surpr.
+87.5%
Revenue
$0.15B
Q4 FY2024
Nov 5, 2024
EPS Actual
$0.06
EPS Est.
$0.06
EPS Surpr.
+0.0%
Revenue
$0.14B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.32 | $0.33 | $0.33 | 1 |
| Q3 FY2028 | $0.24 | $0.24 | $0.24 | 1 |
| Q2 FY2028 | $0.31 | $0.32 | $0.32 | 1 |
| Q1 FY2028 | $0.21 | $0.21 | $0.21 | 1 |
| Q4 FY2027 | $0.28 | $0.28 | $0.28 | 1 |
| Q3 FY2027 | $0.22 | $0.23 | $0.23 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.2B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +66.7% | $10.68 | $10.92 | +2.25% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +9.1% | $8.47 | $9.10 | +7.44% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -30.2% | $6.56 | $7.55 | +15.09% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -4.5% | $6.14 | $7.29 | +18.73% |
| ▲ Q2 FY2025 | May 6, 2025 | +33.3% | $7.03 | $6.20 | -11.81% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +87.5% | $8.76 | $10.80 | +23.29% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +0.0% | $13.71 | $11.48 | -16.27% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +171.4% | $6.26 | $8.09 | +29.23% |
Q2 FY2026+2.25%
Report Date
May 6, 2026
EPS Beat/Miss
+66.7%
Price Before
$10.68
Price After
$10.92
Q1 FY2026+7.44%
Report Date
Mar 5, 2026
EPS Beat/Miss
+9.1%
Price Before
$8.47
Price After
$9.10
Q4 FY2025+15.09%
Report Date
Nov 4, 2025
EPS Beat/Miss
-30.2%
Price Before
$6.56
Price After
$7.55
Q3 FY2025+18.73%
Report Date
Aug 6, 2025
EPS Beat/Miss
-4.5%
Price Before
$6.14
Price After
$7.29
Q2 FY2025-11.81%
Report Date
May 6, 2025
EPS Beat/Miss
+33.3%
Price Before
$7.03
Price After
$6.20
Q1 FY2025+23.29%
Report Date
Mar 11, 2025
EPS Beat/Miss
+87.5%
Price Before
$8.76
Price After
$10.80
Q4 FY2024-16.27%
Report Date
Nov 5, 2024
EPS Beat/Miss
+0.0%
Price Before
$13.71
Price After
$11.48
Q3 FY2024+29.23%
Report Date
Aug 6, 2024
EPS Beat/Miss
+171.4%
Price Before
$6.26
Price After
$8.09
Avg Beat Reaction+5.69%
Avg Miss Reaction+16.91%
Beat Rate6 / 8 quarters
Largest Move+29.23% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BVS ends December
Bioventus Inc. (BVS) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.15 — beating the analyst consensus of $0.09 by +66.7%. BVS has beaten EPS estimates for 2 consecutive quarters. The next BVS earnings date is expected around September 1, 2026.
Each quarter, investors track BVS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BVS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BVS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BVS earnings · 5 questionsBioventus Inc.'s next earnings report is expected around September 1, 2026. BVS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BVS historically reports after market close (AMC).
BVS earnings datewhen is BVS earningsBVS next earnings datewhen does BVS report earningsBVS earnings calendar
▸ Source: FMP · Bioventus Inc. SEC filings · US GAAP · Bioventus Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026